Teva Pharmaceutical Industries Investor Presentation — April 2021

Document content

Teva Pharmaceutical Industries Ltd .

First Quarter 2021 Results

April 28, 2021Cautionary Note Regarding Forward -Looking Statements

This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , which are based on management ’s current beliefs and expectations and are subject to

substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements todiffer significantly from that expressed or implied by such forward -looking statements.

Important factors that could cause or contribute to such differences include risks relating to :

•our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; c onsolidation of our customer base and commercial alliances among our customers; delays in

launches of new generic products; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; our ability to develop and

commercialize biopharmaceutical products; competition for our specialty products, including AUSTEDO®, AJOVY®and COPAXONE®; our ability to achieve expected results from investments in our product pipeline; our

ability to develop and commercialize additional pharmaceutical products; and the effectiveness of our patents and other measu resto protect our intellectual property rights;

•our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our

inability to raise debt or borrow funds in amounts or on terms that are favorable to us;

•our business and operations in general, including: uncertainty regarding the COVID -19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in gen eral; our

ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID -19 pandemic and associated costs therewith; effectiveness of our

optimization efforts; our ability to attract, hire and retain highly skilled personnel; manufacturing or quality control prob lems; interruptions in our supply chain; disruptions of information technology systems; breaches of our

data security; variations in intellectual property laws; challenges associated with conducting business globally, including p olitical or economic instability, major hostilities or terrorism; costs and delays resulting from the

extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the COVID -19 pandemic; the effects of reforms in healthcare